比较土耳其单中心研究中年轻和老年慢性淋巴细胞白血病患者的临床特征和生存情况。
Comparison of clinical features and survival between young and old chronic lymphocytic leukemia patients: a single center study from Turkey.
机构信息
a Department of Hematology , İstanbul Training and Research Hospital, University of Health Sciences , İstanbul , Turkey.
b Department of Internal Medicine , University of Health Sciences, Bağcılar Training and Research Hospital , İstanbul , Turkey.
出版信息
Leuk Lymphoma. 2019 Mar;60(3):742-747. doi: 10.1080/10428194.2018.1509316. Epub 2018 Sep 6.
We aimed to investigate whether the clinical characteristics, the rate of treatment demand and survival differ between chronic lymphocytic leukemia (CLL) patients <65 years (y) and ≥65 y. Sixty three (46%) patients were <65 y and 74 (54%) were ≥65 y. 28.6% (18/63) of the patients <65 required treatment, while this rate was 44.6% (33/74) for patients ≥65 y (p > .05). The probability of overall survival (OS) was 90 vs. 51% in patients <65 y and ≥65 y (p = .016). In univariate analysis, the age affected OS (p = .04, HR: 0.212, CI: 0.047-0.946). In subgroup analysis, in treated patients, the probability of OS was 73 vs. 49% in patients <65 y and ≥65 y (p = .389). The survival difference between the young and old patients is too high to be ignored and age seems to affect the outcome of CLL patients.
我们旨在探究年龄<65 岁和≥65 岁的慢性淋巴细胞白血病（CLL）患者在临床特征、治疗需求率和生存率方面是否存在差异。63 名（46%）患者年龄<65 岁，74 名（54%）患者年龄≥65 岁。28.6%（18/63）的<65 岁患者需要治疗，而≥65 岁患者的这一比例为 44.6%（33/74）（p>.05）。<65 岁患者的总生存率（OS）为 90%，而≥65 岁患者为 51%（p=.016）。在单因素分析中，年龄影响 OS（p=.04，HR：0.212，CI：0.047-0.946）。在亚组分析中，在接受治疗的患者中，<65 岁和≥65 岁患者的 OS 概率分别为 73%和 49%（p=.389）。年轻患者和老年患者之间的生存差异太大，不容忽视，而且年龄似乎影响 CLL 患者的预后。
Zotero 插件